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We provided evidence that the TLR9 engagement of innate immune cells present in the tumor microenvironment by
CpG-oligodeoxynucleotide (CpG-ODN) induces down-modulation of DNA repair gene expression in tumor cells,
sensitizing cancer cells to DNA-damaging chemotherapy. These findings expand the benefits of CpG-ODN therapy
beyond induction of a strong immune response.
Synthetic oligodeoxynucleotides contain-
ing dinucleotides with unmethylated CpG
motifs (CpG-ODN) are agonists of Toll-
like receptor 9 (TLR9), which is expressed
on cells of the immune system as well as
on endothelial cells, fibroblasts, and epi-
thelial cells.
1 In the last decade, TLR9
agonists have been included in the arsenal
of anti-cancer drugs, and successes in
preclinical studies using CpG-ODN and
early indications of their safe use in
humans have generated considerable
interest in the clinical development of
these agents for the treatment of cancer.
1
Experiments in murine models suggested
that CpG-ODN can enhance the response
to ionizing radiotherapy (RT),
2 which kills
cancer by damaging DNA, and to DNA-
damaging chemotherapies,
3,4 although both
of these therapies induce immune suppres-
sion. We hypothesized that the success of
such combinations may be related to the
ability of CpG-ODN to modulate genes
involved in the repair of DNA damaged by
chemo- or radiotherapy. In our manuscript
entitled “TLR9 agonists oppositely modu-
late DNA repair genes in tumor versus
immune cells and enhance chemotherapy
effects,”
5 we showed in a mouse model of
human IGROV-1 ovarian cancer that
treatment with a CpG-ODN sequence
specific for murine TLR9 induce down-
modulation of DNA repair genes in the
tumor cells. Peritumoral injection of CpG-
ODN in the peritoneal cavity was found
to be critical for inducing this down-
modulation. CpG-ODN did not interact
directly with thehumanIGROV-1 cells due
to the oligonucleotide’s species specificity
and to the lack of TLR9 expression in this
cell line, raising the possibility that peritu-
moral TLR9-expressing cells, such as innate
immune cells, and/or endothelial cells,
fibroblasts and epithelial cells,inducedown-
regulation of DNA repair in tumor cells
through a direct cell-cell interaction and/or
by secreting soluble factors. The combina-
tion of cisplatin and CpG-ODN to treat
IGROV-1 ovarian tumor xenografts grow-
ing in the peritoneal cavity of athymic mice
induced a remarkable increase in lifespan
compared with that using either reagent
alone, which can be attributed to the CpG-
ODN-induced modulation of a cohort
of DNA repair genes that cooperatively
influence the ability of cells to repair drug-
induced DNA damage. The relevance of
this cohort of genes in increasing sensitivity
to DNA damage was analyzed on micro-
array data sets containing the gene expres-
sion data of ovarian
6 and breast cancer
7
samples obtained at initial cytoreductive
surgery from patients who then received
primary chemotherapy. Cisplatin-treated
ovarian carcinoma patients as well as
anthracycline-treated breast cancer patients,
who showed expression levels of DNA
repair genes similar to those observed in
IGROV-1 xenografts treated with CpG-
ODN, displayed a significantly poorer
outcome compared with patients expressing
DNArepairgenelevelsdissimilartothoseof
CpG-ODN-treated tumors. The combined
data from our experimental and in silico
analysesrevealed modulation ofDNA repair
genes in both murine colon carcinoma cells
8
and human ovarian carcinoma cells, sug-
gesting that this effect is not restricted to a
specific cancer cell histotype.
In contrast to the down-modulation of
DNA repair genes in tumor cells, in silico
analyses of the effects of CpG-ODN treat-
ment on immune cells
9 revealed essentially
an upmodulation of DNA repair genes.
TheCpG-ODN-induceddown-modulation
in tumor cells and the upmodulation in
immune cells might reflect a physiological
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phenomenon that occurs locally during an
infectious event. Thus, upon detection of
an infectious agent via TLR9, immune
cells might regulate DNA repair genes to
decrease their susceptibility to possible pro-
apoptotic signals during infections while
directly and/or indirectly inducing modu-
lation of DNA repair genes in infected
(or transformed) cells to facilitate their
death (Fig.1). Insignificant modulations of
these genes observed in normal muscle cells
suggest that CpG-ODN-activated immune
cells induce down-modulation of DNA
repair genes only in “altered” cells expres-
sing apposite receptors.
Together, our data provide the first
evidence that TLR9-expressing cells pre-
sent in the tumor microenvironment can
sensitize cancer cells to DNA-damaging
chemotherapy. The opposite changes in
DNA repair gene expression levels
observed in immune and tumor cells point
to the promise of CpG-ODN as an avenue
toward improving chemotherapy treat-
ment without increasing drug toxicity in
tumor patients. Moreover, these findings
confirm the importance of the intratu-
moral route of administration for TLR9
agonists, as we previously reported,
10 and
may explain why association of CpG-
ODN with DNA-damaging drugs has
thus far not reached its full potential to
improve clinical outcome.
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Figure1. Hypothesized mechanisms of action of TLR9-expressing cells in modulating DNA repair
genes during infections. (A) TLR9-positive cells upon detecting an infectious agent regulate DNA
repair genes to decrease their susceptibility to proapoptotic signals and (B) induce modulation of
DNA repair genes in infected cells (C) to facilitate their death.
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